Evidence map›Paper›PMID 35032308›Full record

ArticleAnnals of nuclear medicine2022

Yujing Du, Zhao Chen, Xiaojiang Duan, Ping Yan, Chunli Zhang, Lei Kang, Rongfu Wang

Abstract read
PubMed Publisher
In one paragraph

Article in Annals of nuclear medicine, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
1.3field-weighted citation impact, top 22% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 9 citations in OpenAlex.

  1. Review
  2. IL13Rα2-Targeting Antibodies for Immuno-PET in Solid Malignancies.Journal of nuclear medicine : official publication, Society of Nuclear Medicine · 2025
    Article
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 1 institution in 1 country.

Yujing Du *Department of Nuclear Medicine, Peking University First Hospital, No.8, Xishiku Street, Xicheng District, Beijing, 100034, China.
Zhao Chen *Department of Nuclear Medicine, Peking University First Hospital, No.8, Xishiku Street, Xicheng District, Beijing, 100034, China.
Xiaojiang DuanDepartment of Nuclear Medicine, Peking University First Hospital, No.8, Xishiku Street, Xicheng District, Beijing, 100034, China. duanxj@pku.edu.cn.
Ping YanDepartment of Nuclear Medicine, Peking University First Hospital, No.8, Xishiku Street, Xicheng District, Beijing, 100034, China.
Chunli ZhangDepartment of Nuclear Medicine, Peking University First Hospital, No.8, Xishiku Street, Xicheng District, Beijing, 100034, China.
Lei KangDepartment of Nuclear Medicine, Peking University First Hospital, No.8, Xishiku Street, Xicheng District, Beijing, 100034, China.
Rongfu WangDepartment of Nuclear Medicine, Peking University First Hospital, No.8, Xishiku Street, Xicheng District, Beijing, 100034, China. rongfu_wang@163.com.ORCID http://orcid.org/0000-0002-3839-7520
Peking University · CN

Funding

Beijing Municipal Science and Technology Project Z181100001618017Clinical Medicine PlusX-project of Peking University BMU2018MI010Development of Major Research Equipment and Instruments 2011YQ03011409the Twelfth "Five-Year" Plan for Science and Technology Support 2014BAA03B03
6 · The paper itself

Abstract

objectivePep-1 (CGEMGWVRC) can potently bind to interleukin 13 receptor α 2 (IL-13Rα2), a tumor-restricted receptor found to be expressed in various malignancies. In this study, we intended to prepare a

methodsThe Pep-1 was designed and radiolabeled with

results

conclusionsThis work demonstrated that

Indexed as

Uterine Cervical NeoplasmsAnimalsCell Line, TumorFemaleHumansMicePeptidesProspective StudiesReceptors, Interleukin-13TechnetiumTissue DistributionPeptidesReceptors, Interleukin-13Technetium99mTcInterleukin-13 receptor α 2PeptidesSPECTTumor imaging

Identifiers

PMID35032308
OpenAlexW4205678309

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.